BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

VBL Therapeutics 

6 Jonathan Netanyahu Street

Or Yehuda    60376  Israel
Phone: 97-236-346450 Fax: 97-236-346449


SEARCH JOBS


Industry
Biotechnology






 Company News
VBL Therapeutics Announces Novel Mechanistic Data For VB-201 – A First In Class Orally Available Anti-Inflammatory Compound That Inhibits CD14-TLR4 And TLR2-Dependent Innate Cell Activation 12/6/2013 9:03:27 AM    More...
VBL Therapeutics Receives FDA Fast Track Designation For Lead Compound VB-111 11/27/2013 9:51:34 AM    More...
VBL Therapeutics To Host A Satellite Symposium On VB-111, A Novel Drug For Recurrent GBM At The 2013 Scientific Meeting Of The Society For Neuro-Oncology 11/19/2013 6:30:07 AM    More...
VBL Therapeutics Discloses Data About VB-201 Novel Mechanism and Pre-Clinical Efficacy in Atherosclerosis 7/8/2013 10:12:52 AM    More...
VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival with This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme 6/3/2013 12:31:20 PM    More...
VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival With This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme 6/3/2013 10:21:51 AM    More...
Successful Phase One Demonstrates Tumor Response With Increased Overall Survival for Lead VBL Therapeutics Compound in Cancer 5/16/2013 12:01:38 PM    More...
VBL Therapeutics Presents Positive Preclinical Data for VB-201 in Inflammatory Bowel Disease at Digestive Disease Week (DDW) 2012 5/21/2012 10:17:31 AM    More...
VBL Therapeutics Presents Positive Phase 2 Data for VB-201 in Psoriasis and Atherosclerosis at the Late-Breaking Abstract Session of the American Academy of Dermatology 70th Annual Meeting 3/19/2012 6:58:39 AM    More...
VBL Therapeutics to Present at the UBS Global Life Sciences Conference 9/13/2011 10:36:19 AM    More...
1234

//-->